Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety,
tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and
refractory Non-Hodgkin's lymphoma and multiple myeloma.